PT - JOURNAL ARTICLE AU - Sarjomaa, Marjut AU - Diep, Lien My AU - Zhang, Chi AU - Tveten, Yngvar AU - Reiso, Harald AU - Thilesen, Carina AU - Nordbø, Svein Arne AU - Berg, Kristine Karlsrud AU - Aaberge, Ingeborg AU - Pearce, Neil AU - Kersten, Hege AU - Vandenbroucke, Jan Paul AU - Eikeland, Randi AU - Møller Fell, Anne Kristin TI - SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway AID - 10.1101/2022.02.16.22271075 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.16.22271075 4099 - http://medrxiv.org/content/early/2022/02/21/2022.02.16.22271075.short 4100 - http://medrxiv.org/content/early/2022/02/21/2022.02.16.22271075.full AB - Objectives To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS CoV-2) spike protein up to 12 months after Coronavirus Disease (COVID-19) infection in non-vaccinated individuals and the possible predictors of antibody persistence.Methods This is a prospective multi-centre longitudinal cohort study.Participants The study included SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) positive and negative participants in South-Eastern Norway from February to December 2020. Possible predictors of SARS-CoV-2 total antibody persistence was assessed. The SARS-CoV-2 total antibody levels against spike protein were measured three to five months after PCR in 391 PCR-positive and 703 PCR-negative participants; 212 PCR-positive participants were included in follow-up measurements at 10 to 12 months. The participants completed a questionnaire including information about symptoms, comorbidities, allergies, body mass index (BMI), and hospitalisation.Primary outcome The SARS-CoV-2 total antibody levels against spike protein three to five and 10 to 12 months after PCR positive tests.Results SARS-CoV-2 total antibodies against spike protein were present in 366 (94%) non-vaccinated PCR-positive participants after three to five months, compared with nine (1%) PCR-negative participants. After 10 to 12 months, antibodies were present in 204 (96%) non-vaccinated PCR-positive participants. Of the PCR-positive participants, 369 (94%) were not hospitalised. The mean age of the PCR-positive participants was 48 years (SD 15, range 20-85) and 50% of them were male. BMI ≥ 25 kg/m2 was positively associated with decreased antibody levels (OR 2.34, 95% CI 1.06 to 5.42). Participants with higher age and self-reported initial fever with chills or sweating were less likely to have decreased antibody levels (age: OR 0.97, 95% CI 0.94 to 0.99; fever: OR 0.33, 95% CI 0.13 to 0.75).Conclusion Our results indicate that the level of SARS-CoV-2 total antibodies against spike protein persists for the vast majority of non-vaccinated PCR-positive persons at least 10 to 12 months after mild COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04514003Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent before inclusion. The Study was approved by the Regional Committee for Medical and Health Research Ethics of South East Norway A (Number 146469), Norwegian Centre for Research Data (NSD), and Data Protection Officers in the participating hospitals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be shared publicly because of restrictions on data availability from the Regional Committees for Medical and Health Research Ethics in South-Eastern Norway due to sensitive and not fully anonymised data. Further, the study is ongoing and data analyses have not been completed.